A Randomized Phase II Preoperative Study of Autophagy Inhibition with High-Dose Hydroxychloroquine and Gemcitabine/Nab-Paclitaxel in Pancreatic Cancer Patients.
Herbert J ZehNathan BaharyBrian A BooneAatur D SinghiJennifer Lee Miller-OcuinDaniel P NormolleAmer H ZureikatMelissa E HoggDavid L BartlettKenneth K LeeAllan TsungJ Wallis MarshPranav MurthyDaolin TangNatalie SeiserRavi K AmaravadiVirginia EspinaLance LiottaMichael T LotzePublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
The addition of hydroxychloroquine to preoperative gemcitabine and nab-paclitaxel chemotherapy in patients with resectable pancreatic adenocarcinoma resulted in greater pathologic tumor response, improved serum biomarker response, and evidence of autophagy inhibition and immune activity.
Keyphrases
- locally advanced
- phase ii
- high dose
- neoadjuvant chemotherapy
- rectal cancer
- clinical trial
- cell death
- patients undergoing
- squamous cell carcinoma
- endoplasmic reticulum stress
- signaling pathway
- oxidative stress
- advanced non small cell lung cancer
- open label
- radiation therapy
- chemotherapy induced
- randomized controlled trial
- stem cell transplantation
- phase iii
- placebo controlled
- epidermal growth factor receptor